{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:15:42Z","timestamp":1793153742722,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the pregnancy outcomes on patients with chronic migraine exposed to onabotulinumtoxinA from Hull Headache Clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraines are common in women of reproductive age and those with chronic migraine have a major impact on their activities of daily living and health-related quality of life. Apart from low dose amitriptyline and beta-blockers all other prophylactic agents have proven teratogenic effects. OnabotulinumtoxinA is approved as preventive treatment for adult patients with chronic migraine, although its impact on pregnancy is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively collected data for efficacy and safety on all patients treated with onabotulinumtoxinA at the Hull Headache Clinic. The toxin is administered as per PREEMPT paradigm. Female patients of reproductive age group receiving onabotulinumtoxinA are given advice on contraception and the unknown impact of the toxin on pregnancy. They are asked to report pregnancy when they are appraised on the risk\/benefit of treatment continuation. All patients are consented for access to their medical records and pregnancy outcome and those who wished to continue are asked to sign a disclaimer. Pregnancy outcome data was collected on all patients for the mode of delivery, birth weight and congenital malformation and any other unexpected outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 9\u2009years period 45 patients reported pregnancy while receiving onabotulinumtoxinA. All patients had received onabotulinumtoxinA within 3 months prior to the date of conception. 32 patients wished to continue treatment during pregnancy while the remaining 13 stopped treatment. Apart from 1 miscarriage in the treatment group, all patients had full term healthy babies of normal birth weight and no congenital malformations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We report our experience of 45 patients exposed to onabotulinumtoxinA during pregnancy. Although the numbers are small, there was no impact of the toxin found on the pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-020-01196-1","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T09:03:09Z","timestamp":1603962189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Ho-Tin","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modar","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-0889","authenticated-orcid":false,"given":"Fayyaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"1196_CR1","first-page":"106","volume":"18","author":"A Negro","year":"2017","unstructured":"Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B, Terrin A, Reuter U (2017) D D Mitsikotas on behalf of the European headache federation school of advanced studies. Headache Pregnancy 18:106","journal-title":"Headache Pregnancy"},{"issue":"5","key":"1196_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/pnp.137","volume":"13","author":"A MacGregor","year":"2009","unstructured":"MacGregor A (2009) Management of migraine during pregnancy. Prog Neurol Psychiatry 13(5):21\u201324","journal-title":"Prog Neurol Psychiatry"},{"issue":"2","key":"1196_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","volume":"77","author":"J Morrow","year":"2006","unstructured":"Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R et al (2006 Feb) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register. J Neurol Neurosurg Psychiatry 77(2):193\u2013198","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1196_CR4","volume-title":"Botulinum toxin type a for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance","author":"NICE[TA260]","year":"2012","unstructured":"NICE[TA260] (2012) Botulinum toxin type a for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance Accessed on 30 Sept 2020"},{"issue":"6","key":"1196_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.7205\/MILMED-D-13-00477","volume":"179","author":"AY Robinson","year":"2014","unstructured":"Robinson AY, Grogan PM (2014) OnabotulinumA successfully used as a migraine prophylaxis during pregnancy: a case report. Mil Med 179(6):703\u2013704","journal-title":"Mil Med"},{"issue":"15","key":"1196_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1129-2377-15-S1-G1","volume":"54","author":"M Khalil","year":"2014","unstructured":"Khalil M, Zafar HW, Quarshie V, Ahmed F (2014) Prospective analysis of the use of OnabotulinumtoxinA (Botox) in the treatment of chronic migraine; a real-life data in 254 patients from hull, UK. J Headache Pain 54(15):1\u20139","journal-title":"J Headache Pain"},{"issue":"6","key":"1196_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 50(6):921\u2013936","journal-title":"Headache."},{"key":"1196_CR8","first-page":"117","volume-title":"Botulinum toxin a during pregnancy: a survey of treating physicians","author":"JC Morgan","year":"2006","unstructured":"Morgan JC, Iyer SS, Moser ET, Singer C, Sethi KD (2006) Botulinum toxin a during pregnancy: a survey of treating physicians, vol 77. J Neurol, Neurosurg Psychiatry, pp 117\u2013119"},{"key":"1196_CR9","unstructured":"MRHA. Botox 50 Allergan Units Powder for Solution for Injection (Botulinum Toxin Type A) - PL 00426\/0118. \n                  https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/61c8e659aa05dd44228dd89360c8d8b77288ed18\n                  \n                 Accessed on 30 Sept 2020"},{"key":"1196_CR10","unstructured":"FDA. Botox Label. \n                  https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103000s5232lbl.pdf\n                  \n                . :2011. Accessed on 30 Sept 2020"},{"key":"1196_CR11","unstructured":"NHS. \n                  www.nhs.uk\/conditions\/miscarriage\n                  \n                . Accessed on 30 Sept 2020"},{"key":"1196_CR12","first-page":"1","volume":"60","author":"SJ Ventura","year":"2012","unstructured":"Ventura SJ, Curtin SC, Abma JC, Henshaw SK (2012) Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Natl Vital Stat Rep 60:1\u201321","journal-title":"Natl Vital Stat Rep"},{"issue":"8","key":"1196_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/bdra.23150","volume":"97","author":"R Sokal","year":"2013","unstructured":"Sokal R, Fleming KM, Tata LJ (2013) Potential of general practice data for congenital anomaly research: comparison with registry data in the United Kingdom. Birth Defects Res A Clin Mol Teratol 97(8):546\u2013553","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"1196_CR14","first-page":"tre-02-85-417-1","volume":"2","author":"M Brodsky","year":"2012","unstructured":"Brodsky M, Swope DM, Grimes DA (2012) Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y) 2:tre-02-85-417-1","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"5","key":"1196_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0041-0101(03)00196-X","volume":"42","author":"DD-S Tang-Liu","year":"2003","unstructured":"Tang-Liu DD-S, Aoki KR, Dolly JO, de Paiva A, Houchen TL, Chasseaud LF et al (2003) Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 42(5):461\u2013469","journal-title":"Toxicon."},{"issue":"1","key":"1196_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/practneurol-2013-000621","volume":"14","author":"CS Pearce","year":"2014","unstructured":"Pearce CS (2014) Can I treat this pregnant patient with botulinum toxin? Pract Neurol 14(1):32\u201333","journal-title":"Pract Neurol"},{"key":"1196_CR17","unstructured":"Allergan. Highlights of Prescribing Information (BOTOX). \n                  https:\/\/www.allergan.com\/assets\/pdf\/botox_pi.pdf\n                  \n                . 2012. Accessed 30 Sept 2020"},{"issue":"2","key":"1196_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/pds.3920","volume":"25","author":"MF Brin","year":"2016","unstructured":"Brin MF, Kirby RS, Slavotinek A, Miller-Messana MA, Parker L, Yushmanova I et al (2016) Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf 25(2):179\u2013187","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1196_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/nejm199609123351117","volume":"335","author":"L Robin","year":"1996","unstructured":"Robin L, Herman D, Redett R (1996) Botulism in a pregnant woman. New Eng J Med 335:823\u2013824. \n                  https:\/\/doi.org\/10.1056\/nejm199609123351117","journal-title":"New Eng J Med"},{"key":"1196_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2044.2005.04434.x","volume":"61","author":"GA Morrison","year":"2006","unstructured":"Morrison GA, Lang C, Huda S (2006) Botulism in a pregnant intravenous drug abuser. Anaesthesia 61:57\u201360. \n                  https:\/\/doi.org\/10.1111\/j.1365-2044.2005.04434.x","journal-title":"Anaesthesia"},{"issue":"05","key":"1196_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/s0140-6736","volume":"348","author":"JM Polo","year":"1996","unstructured":"Polo JM, Mart\u00edn J, Berciano J (1996) Botulism and pregnancy. Lancet 348(05):195, 66139\u2013199. \n                  https:\/\/doi.org\/10.1016\/s0140-6736","journal-title":"Lancet"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-020-01196-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T01:11:09Z","timestamp":1604020269000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01196-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01196-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-89348\/v1","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a prospective audit of patients treated at a tertiary headache centre in a real-life setting. Ethical approval was not required as the treatment given was based on the clinical needs. The clinical care did not involve anything being done to patients beyond their normal clinical management. The choice of whether to continue or stop onabotulinumtoxinA was made by the patient after careful and detailed counselling and appraisal on the risk-benefit evaluation. Patient, however, did sign a disclaimer that a formal appraisal had taken place and was documents in patients\u2019 notes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fayyaz Ahmed has received honorarium for being on the advisory board of Allergan, Novartis, TEVA, Eli Lilly, Electrocore, Eneura paid to the charitable organisations i.e., British Association for the Study of Headache (BASH), Migraine Trust (MT) and Anglo-Dutch Migraine Association (ADMA).Ho-Tin Wong and Modar Khalil have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}